<code id='4775BB8DCD'></code><style id='4775BB8DCD'></style>
    • <acronym id='4775BB8DCD'></acronym>
      <center id='4775BB8DCD'><center id='4775BB8DCD'><tfoot id='4775BB8DCD'></tfoot></center><abbr id='4775BB8DCD'><dir id='4775BB8DCD'><tfoot id='4775BB8DCD'></tfoot><noframes id='4775BB8DCD'>

    • <optgroup id='4775BB8DCD'><strike id='4775BB8DCD'><sup id='4775BB8DCD'></sup></strike><code id='4775BB8DCD'></code></optgroup>
        1. <b id='4775BB8DCD'><label id='4775BB8DCD'><select id='4775BB8DCD'><dt id='4775BB8DCD'><span id='4775BB8DCD'></span></dt></select></label></b><u id='4775BB8DCD'></u>
          <i id='4775BB8DCD'><strike id='4775BB8DCD'><tt id='4775BB8DCD'><pre id='4775BB8DCD'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:focus    Page View:5377
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In